Key facts
- Novorex’s last known valuation is $40.6M (Apr 2026).
- It has raised $33.2M; the latest was Later Stage VC ($14.0M) in Apr 2026.
- Notable investors include Tech Incubator Program for Startup, SBI Investment, KB Investment, Korea Development Bank, Hana Ventures — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Novorex
- ·The full record, as it builds
Funding rounds
No funding rounds for Novorex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Novorex
Developer of a biotechnology platform designed to accelerate drug discovery for challenging biological targets. The company offers AI (artificial intelligence)-driven molecular prediction, fragment-based drug design, and biophysical validation, enabling pharmaceutical and biotechnology researchers to identify and optimize small molecule therapeutics for previously inaccessible targets.
- Sector
- Healthcare
- HQ
- Seongnam-si, South Korea
- Founded
- 2020
- Employees
- 28
- Website
- novorex.com/
- Ownership
- Privately Held (backing)
Novorex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Novorex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Novorex in its N-PORT filings yet. We sweep new filings monthly.